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Microbial cell factories provide an interesting alternative to current extraction or chemical synthesis processes for
the production of newly discovered compounds1. The choice of the microbial production host depends on both
the identified molecule and the biochemical synthesis pathway. Here, we present an alkaloids case study from our
recent review about all novel antimicrobial alkaloids discovered in marine fungi since 20152.
 Biochemical hiatuses
 Structure-activity studies required
 Possible correlation antimicrobial activity and other bioactivities
Feel free to contact us for any information regarding this research or 
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